Micafungin-induced hemolytic anemia: a case report and investigation of anti-micafungin antibody prevalence

Key Points

• Hemolytic anemia can occur with micafungin use, raising concerns about its safety.
• The prevalence of anti-micafungin antibodies was investigated, revealing significant immunological responses.
• Observational analysis in a clinical setting highlights the relationship between micafungin and hemolytic anemia.
• Further investigations are necessary to understand long-term implications for micafungin therapy.